Vascular Considerations for Amyloid Immunotherapy

Area of Science:

• Neuroscience
• Immunology
• Neurology

Background:

• Amyloid beta (Aβ) plaque accumulation is a key pathology in Alzheimer's disease (AD), linked to cognitive decline.
• Anti-Aβ immunotherapies are a major research focus for clearing these plaques.
• Cerebrovascular complications, specifically ARIA, are a significant concern with these therapies.

Purpose of the Study:

• To review the historical development of anti-Aβ immunotherapies.
• To analyze clinical findings related to these treatments.
• To provide recommendations for future research and therapeutic strategies.

Main Methods:

• Literature review of animal and human studies on anti-Aβ immunotherapies.
• Analysis of clinical trial data and reported side effects.
• Examination of the mechanisms underlying immunotherapy-induced vascular deficits.

Main Results:

• Anti-Aβ immunotherapies have shown efficacy in reducing Aβ plaques over two decades.
• Amyloid-related imaging abnormalities (ARIA), indicating cerebrovascular compromise, are frequently observed.
• The precise mechanisms driving ARIA remain largely unknown.

Conclusions:

• Despite Aβ clearance, anti-Aβ immunotherapies present significant challenges due to vascular side effects.
• The recent approval of aducanumab highlights the urgent need to address these vascular deficits.
• Future research must prioritize understanding and mitigating ARIA for safer AD treatment development.